Antiverse
Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing.
$9.3MSeries A
ParticipantII
Innovation Investment Capital
Activity from announced rounds
Activity in this selectionmanta-ray-ventures-b2308806
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $9.3M 1 disclosed · full round size, not this investor’s share